Key Points
- Embecta director Milton Mayo Morris sold 6,293 shares for $37,002.84 at an average price of $5.88, reducing his ownership by 10.47% to 53,828 shares.
- Embecta reported quarterly EPS of $0.56, beating the $0.27 analyst estimate, while revenue of $271.7 million exceeded expectations but declined 8.1% year over year.
- Analyst sentiment remains cautious, with the stock carrying an average “Reduce” rating; Bank of America cut its price target to $3, while shares recently traded near $5.55.
Embecta Corp. (NASDAQ:EMBC - Get Free Report) Director Milton Mayo Morris sold 6,293 shares of the business's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $5.88, for a total transaction of $37,002.84. Following the completion of the sale, the director owned 53,828 shares in the company, valued at approximately $316,508.64. This trade represents a 10.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Embecta Trading Down 4.3%
EMBC opened at $5.55 on Wednesday. The firm has a market cap of $314.46 million, a P/E ratio of 3.75 and a beta of 0.86. Embecta Corp. has a 12 month low of $2.77 and a 12 month high of $15.55. The stock has a 50-day moving average of $4.22 and a 200 day moving average of $5.77.
Embecta (NASDAQ:EMBC - Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.29. The business had revenue of $271.70 million for the quarter, compared to the consensus estimate of $254.53 million. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.The company's quarterly revenue was down 8.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, research analysts forecast that Embecta Corp. will post 1.84 earnings per share for the current fiscal year.
Embecta Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Thursday, August 27th will be issued a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.7%. The ex-dividend date is Thursday, August 27th. Embecta's dividend payout ratio is presently 2.70%.
Hedge Funds Weigh In On Embecta
A number of hedge funds have recently added to or reduced their stakes in EMBC. Royal Bank of Canada increased its position in shares of Embecta by 38.3% during the first quarter. Royal Bank of Canada now owns 18,201 shares of the company's stock worth $232,000 after acquiring an additional 5,036 shares during the period. AQR Capital Management LLC grew its stake in Embecta by 3.7% in the first quarter. AQR Capital Management LLC now owns 225,641 shares of the company's stock worth $2,738,000 after purchasing an additional 8,109 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company's stock worth $629,000 after purchasing an additional 1,159 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Embecta by 4.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company's stock worth $2,195,000 after purchasing an additional 7,894 shares during the period. Finally, Jane Street Group LLC raised its position in Embecta by 224.0% during the 1st quarter. Jane Street Group LLC now owns 132,688 shares of the company's stock valued at $1,692,000 after purchasing an additional 91,729 shares in the last quarter. 93.83% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several research analysts have commented on EMBC shares. Weiss Ratings lowered shares of Embecta from a "sell (d+)" rating to a "sell (d)" rating in a research note on Monday, August 3rd. Bank of America reduced their target price on shares of Embecta from $11.00 to $3.00 and set an "underperform" rating on the stock in a research note on Monday, May 18th. Finally, Zacks Research upgraded shares of Embecta from a "strong sell" rating to a "hold" rating in a report on Friday, July 17th. Three research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $11.00.
View Our Latest Analysis on Embecta
About Embecta
(
Get Free Report)
Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.
The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
